The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts

Neoplasia

Volumn 8, Issue 5, 2006, Pages 384-393

  Liu, Yuying ^a   Zhang, Weihe ^a   Cheung, Lawrence H ^a   Niu, Ting ^b   Wu, Qingping ^a   Li, Chun ^a   Van Pelt, Carolyn S ^a   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Immunocytokine; Melanoma; Single chain Fv antibody; Tumor necrosis factor; Tumor xenograft

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; IODINE 125; MELANOMA ANTIGEN; MELANOMA ANTIGEN GP240; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CLINICAL CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LD 50; MAXIMUM TOLERATED DOSE; MELANOMA; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

EID: 33744799701     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06121     Document Type: Article

References (56)

1. Rosenblum M (2004). Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma. Adv Pharmacol 51, 209-228.
2. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, and Rosenblum MG (2002). In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 99, 7866-7871.
3. Liu Y, Cheung LH, Hittelman WN, and Rosenblum MG (2003). Targeted delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2, 1341-1350.
4. Liu Y, Cheung LH, Marks JW, and Rosenblum MG (2004). Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. Int J Cancer 108, 549-557.
5. Pastan I and Kreitman RJ (2002). Immunotoxins in cancer therapy. Curr Opin Invest Drugs 3, 1089-1091.
6. Pastan I (2003). Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 52, 338-341.
7. Chan MC and Murphy RM (1999). Kinetics of cellular trafficking and cytotoxicity of 9.2.27-gelonin immunotoxins targeted against the high-molecular-weight melanoma-associated antigen. Cancer Immunol Immunother 47, 321-329.
8. Murphy JR, Lakkis FG, vanderSpek JC, Anderson P, and Strom TB (1992). Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease. Target Diagn Ther 7, 365-382.
9. Reisfeld RA, Gillies SD, Mendelsohn J, Varki NM, and Becker JC (1996). Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. Cancer Res 56, 1707-1712.
10. Reisfeld RA, Becker JC, and Gillies SD (1997). Immunocytokines: a new approach to immunotherapy of melanoma. Melanoma Res 7 (Suppl 2), S99-S106.
11. Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X, Lo KM, Lan Y, Super M, Gillies SD, et al. (1997). Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 57, 4948-4955.
12. Rosenblum MG, Cheung L, Mujoo K, and Murray JL (1995). An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunol Immunother 40, 322-328.
13. Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, and Kavanagh JJ (1999). Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 5, 953-961.
14. Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, and Casadevall A (2004). Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci USA 101, 14865-14870.
15. Kantor RR, Ng AK, Giacomini P, and Ferrone S (1982). Analysis of the NIH workshop monoclonal antibodies to human melanoma antigens. Hybridoma 1, 473-482.
16. Dell'Erba L, Calo-Gabrieli G, Caruso ML, Thomas R, Cortino G, Valentini AM, Muto P, Albrizio M, Pastena MI, and Lastoria S (2001). Immunohistochemical reactivity of anti-melanoma monoclonal antibody 225.28S in human breast cancer biopsies. Anticancer Res 21, 925-930.
17. Graf LH Jr and Ferrone S (1989). Human melanoma-associated antigens. Immunol Ser 43, 643-679.
18. Kantor RR, Albino AP, Ng AK, and Ferrone S (1986). Biosynthesis and intracellular processing of four human melanoma associated antigens. Cancer Res 46, 5223-5228.
19. Macey DJ, Denardo SJ, Denardo GL, Goodnight JK, and Unger MW (1988). Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. Am J Physiol Imaging 3, 1-6.
20. 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88. Cancer Immunol Immunother 39, 397-400.
21. Mujoo K, Cheung L, Murray JL, and Rosenblum MG (1995). Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother 40, 339-345.
22. Rosenblum MG, Murray JL, Cheung L, Rifkin R, Salmon S, and Bartholomew R (1991). A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol Biother 3, 6-13.
23. Atwell JL, Breheney KA, Lawrence LJ, McCoy AJ, Kortt AA, and Hudson PJ (1999). scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 12, 597-604.
24. Adams GP and Schier R (1999). Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods 231, 249-260.
25. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, and Batra SK (1998). Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 42, 225-241.
26. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, and Whitlow M (1988). Single-chain antigen-binding proteins. Science 242, 423-426.
27. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, and Schlom J (1990). In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82, 1191-1197.
28. Rosenblum MG, Cheung L, Murray JL, and Bartholomew R (1991). Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun 3, 21-27.
29. Rosenblum MG, Cheung L, Kim SK, Mujoo K, Donato NJ, and Murray JL (1996). Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells. Cancer Immunol Immunother 42, 115-121.
30. Rosenblum MG, Marks JW, and Cheung LH (1999). Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Cancer Chemother Pharmacol 44, 343-348.
31. Rosenblum MG, Cheung LH, Liu Y, and Marks JW III (2003). Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 63, 3995-4002.
32. Aggarwal BB and Natarajan K (1996). Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 7, 93-124.
33. Borish LC and Steinke JW (2003). 2. Cytokines and chemokines. J Allergy Clin Immunol 111, S460-S475.
34. Shiohara M, Gombart AF, Berman JD, Koike K, Komiyama A, and Koeffler HP (1997). Cytostatic effect of TNFalpha on cancer cells is independent of p21WAF1. Oncogene 15, 1605-1609.
35. Zouboulis CC, Schroder K, Garbe C, Krasagakis K, Kruger S, and Orfanos CE (1990). Cytostatic and cytotoxic effects of recombinant tumor necrosis factor-alpha on sensitive human melanoma cells in vitro may result in selection of cells with enhanced markers of malignancy. J Invest Dermatol 95, 223S-230S.
36. Koshita Y, Lu Y, Fujii S, Neda H, Matsuyama T, Satoh Y, Itoh Y, Takahashi M, Kato J, and Sakamaki S (1995). Efficacy of TNF-alpha gene-transduced tumor cells in treatment of established in vivo tumor. Int J Cancer 63, 130-135.
37. Hwu P, Yannelli J, Kriegler M, Anderson WF, Perez C, Chiang Y, Schwarz S, Cowherd R, Delgado C, and Mule J (1993). Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J Immunol 150, 4104-4115.
38. Mizuguchi H, Nakagawa T, Toyosawa S, Nakanishi M, Imazu S, Nakanishi T, Tsutsumi Y, Nakagawa S, Hayakawa T, Ijuhin N, et al. (1998). Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. Cancer Res 58, 5725-5730.
39. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, and Ching LM (1999). Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59, 633-638.
40. Scherf U, Benhar I, Webber KO, Pastan I, and Brinkmann U (1996). Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells. Clin Cancer Res 2, 1523-1531.
41. Yang J, Moyana T, and Xiang J (1995). A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor. Mol Immunol 32, 873-881.
42. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, and Spies T (2001). Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53, 279-287.
43. Osborne CK, Hobbs K, and Clark GM (1985). Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45, 584-590.
44. Helmbach H, Rossmann E, Kern MA, and Schadendorf D (2001). Drug-resistance in human melanoma. Int J Cancer 93, 617-622.
45. Leong SP (2003). Future perspectives on malignant melanoma. Surg Clin North Am 83, 453-456.
46. Kuroda K, Miyata K, Fujita F, Koike M, Fujita M, Nomura M, Nakagawa S, Tsutsumi Y, Kawagoe T, Mitsuishi Y, et al. (2000). Human tumor necrosis factor-alpha mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice. Cancer Lett 159, 33-41.
47. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M, and Urushizaki I (1988). Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 48, 2179-2183.
48. Moritz T, Niederle N, Baumann J, May D, Kurschel E, Osieka R, Kempeni J, Schlick E, and Schmidt CG (1989). Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. Cancer Immunol Immunother 29, 144-150.
49. Blick M, Sherwin SA, Rosenblum M, and Gutterman J (1987). Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47, 2986-2989.
50. Rosenblum MG, Horn SA, and Cheung LH (2000). A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor. Int J Cancer 88, 267-273.
51. Curnis F, Gasparri A, Sacchi A, Longhi R, and Corti A (2004). Coupling tumor necrosis factor-alpha with alpha V integrin ligands improves its antineoplastic activity. Cancer Res 64, 565-571.
52. Hoogenboom HR, Raus JC, and Volckaert G (1991). Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule. Biochim Biophys Acta 1096, 345-354.
53. Lyu MA and Rosenblum MG (2005). The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1. Mol Cancer Ther 4, 1205-1213.
54. Liu Y, Cheung LH, and Rosenblum MG (2001). A recombinant fusion protein scFvMEL/TNF decreases SAPK/JNK activation and induces IkB-alpha degradation in human melanoma cells. Proc AACR 42, 503-2710.
55. Mihara M, Koishihara Y, Fukui H, Yasukawa K, and Ohsugi Y (1991). Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Immunology 74, 55-59.
56. Kuroda K, Miyata K, Shikama H, Kawagoe T, Nishimura K, Takeda K, Sakae N, and Kato M (1995). Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Int J Cancer 63, 152-157.